Akums Drugs (AKUMS) | Stock Overview & Key Data
Akums Drugs Performance Comparison
Stock Range
Today's Range
Low: ₹437.00
High: ₹444.45
on October 7, 2025
52 Week Range
Low: ₹405.00
High: ₹939.95
on April 7, 2025
on October 18, 2024
All-Time High: ₹1,175.90 on August 19, 2024
Explore how other Indian stocks compare to their 52-week ranges: View IN Market 52-Week Insights
Key Statistics
Market Cap
INR70.0B
EPS
22.29
P/E Ratio (TTM)
20.02
Forward P/E
17.77
P/B Ratio
2.24
PEG Ratio
N/A
Div. Yield
N/A
ROE
11.04%
Beta
N/A
Debt to Equity
2.88
Financial Highlights
Profitability
Gross Margin
43.17%
Operating Margin
8.99%
Profit Margin
8.28%
Returns and Earnings
Return on Assets (TTM)
8.22%
Return on Equity (TTM)
11.04%
EBITDA
INR5.3B
Net Income (TTM)
INR3.4B
Growth
Revenue (TTM)
Revenue Per Share (TTM)
INR269.50
Quarterly Revenue Growth (YoY)
0.50%
Quarterly Earnings Growth (YoY)
5.50%
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Akums Drugs AKUMS | 70.01B Mid-cap | -0.54% | -5.34% | -22.57% | 4.72% | -30.27% | -48.51% | -45.05% | -45.05% |
| Sun Pharmaceutical SUNPHARMA | 4.01T Large-cap | 4.12% | 4.66% | -1.50% | -0.70% | -12.45% | -13.00% | 69.49% | 239.84% |
| Divi's Laboratories DIVISLAB | 1.61T Large-cap | 2.26% | -3.33% | -15.42% | 10.79% | -4.06% | -5.14% | 63.08% | 80.80% |
| Neuland Laboratories NEULANDLAB | 194.55B Mid-cap | 5.06% | 4.94% | 28.65% | 38.32% | 6.08% | 6.42% | 892.96% | 1,216.52% |
| Alembic APLLTD | 182.09B Mid-cap | 1.42% | -4.32% | -9.57% | 7.27% | -13.60% | -22.65% | 58.51% | -5.71% |
| Jubilant Pharmova JUBLPHARMA | 173.91B Mid-cap | 3.33% | -0.84% | -8.63% | 24.15% | 1.56% | -4.33% | 239.85% | 111.54% |
Ownership & Short Interest
Insider Ownership
82.12%
Institutional Ownership
7.48%
Shares Short
N/A
Short Ratio
N/A
Short % of Shares Outstanding
N/A
Average 10-Day Volume
145K
Average 90-Day Volume
223K
Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is AKUMS's 52-week high and low?
- In the last 52 weeks, Akums Drugs reached a high of ₹939.95 (on October 18, 2024) and a low of ₹405.00 (on April 7, 2025).
- What is the market cap and P/E ratio for AKUMS?
- Curious about Akums Drugs's size and valuation? Its market capitalization stands at 70.01B. When it comes to valuation, the P/E ratio (trailing twelve months) is 20.02, and the forward P/E (looking ahead) is 17.77.
- Does AKUMS pay dividends? If so, what's the yield?
- As for dividends, Akums Drugs isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Akums Drugs's main competitors or similar companies to consider before investing?
When looking at Akums Drugs, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Sun Pharmaceutical
SUNPHARMA4.01T Healthcare Drug Manufacturers - Specialty & Generic -13.00% 69.49% Divi's Laboratories
DIVISLAB1.61T Healthcare Drug Manufacturers - Specialty & Generic -5.14% 63.08% Neuland Laboratories
NEULANDLAB194.55B Healthcare Drug Manufacturers - Specialty & Generic 6.42% 892.96% Alembic
APLLTD182.09B Healthcare Drug Manufacturers - Specialty & Generic -22.65% 58.51% Jubilant Pharmova
JUBLPHARMA173.91B Healthcare Drug Manufacturers - Specialty & Generic -4.33% 239.85% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Akums Drugs & Pharmaceuticals Ltd.? (e.g., ROE, Debt/Equity)
- To get a sense of Akums Drugs's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 11.04%, the Debt to Equity ratio from the most recent quarter is 2.88, and its Gross Profit Margin stands at 43.17%.
- What is the recent revenue and earnings growth for AKUMS?
- Looking at Akums Drugs's growth, its revenue over the trailing twelve months (TTM) was INR41B. Compared to the same quarter last year (YoY), quarterly revenue grew by 0.50%, and quarterly earnings saw a YoY growth of 5.50%.
- How much of AKUMS stock is held by insiders and institutions?
- Wondering who owns Akums Drugs stock? Company insiders (like executives and directors) hold about 82.12% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 7.48%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.